News Press Releases

InVivo Therapeutics to Participate in Upcoming Investor Conferences

September 6, 2016

- CEO and Chairman Mark Perrin to Present at Rodman & Renshaw and Ladenburg Thalmann Annual Conferences -

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) today announced that the company will participate in two upcoming investor conferences.

Mark Perrin, Chief Executive Office and Chairman, is scheduled to present at the Rodman & Renshaw 18^th Annual Global Investment Conference in New York, NY on Tuesday, September 13 at 5:05 PM EDT. Additional information about the conference can be found at www.rodm.com

Mr. Perrin is also scheduled to present at Ladenburg Thalmann’s 2^nd Annual Healthcare Conference in New York, NY on Tuesday, September 27 at 11:00 AM EDT. The presentation will be available via webcast at http://wsw.com/webcast/ladenburg2/nviv/

“I am pleased to be presenting at both upcoming conferences and look forward to sharing the latest company developments,” Mr. Perrin said.

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.